155 related articles for article (PubMed ID: 2266388)
21. Comparative PET imaging of experimental tumors with bromine-76-labeled antibodies, fluorine-18-fluorodeoxyglucose and carbon-11-methionine.
Lövqvist A; Sundin A; Roberto A; Ahlström H; Carlsson J; Lundqvist H
J Nucl Med; 1997 Jul; 38(7):1029-35. PubMed ID: 9225786
[TBL] [Abstract][Full Text] [Related]
22. [Positron emission tomography of lung cancer using 18F-2-fluoro-2-deoxy-D-glucose and L-[11C-methyl]-methionine].
Matsuzawa T; Fujiwara T; Abe Y; Itoh M; Fukuda H; Yamaguchi K; Kawai H; Kubota K; Yamaguchi T; Miyazawa H
Kokyu To Junkan; 1987 Jan; 35(1):15-20. PubMed ID: 3031787
[No Abstract] [Full Text] [Related]
23. PET for diagnosis of malignant lymphoma of the scalp: comparison of [11C]methyl-L-methionine and [18F]fluoro-2-deoxyglucose.
Tsuyuguchi N; Hakuba A; Okamura T; Ochi H; Suzuki T; Sunada I
J Comput Assist Tomogr; 1997; 21(4):590-3. PubMed ID: 9216763
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
[TBL] [Abstract][Full Text] [Related]
25. [Comparative analysis of the informative value of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography in the differential diagnosis of solitary lung masses].
Tlostanova MS; Avetisian AO; Kozak AR
Vestn Rentgenol Radiol; 2014; (3):13-9. PubMed ID: 25782293
[TBL] [Abstract][Full Text] [Related]
26. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
27. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
[TBL] [Abstract][Full Text] [Related]
28. Detecting recurrent or residual lung cancer with FDG-PET.
Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA
J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
[TBL] [Abstract][Full Text] [Related]
29. Characterization of chest masses by FDG positron emission tomography.
Hübner KF; Buonocore E; Singh SK; Gould HR; Cotten DW
Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
[TBL] [Abstract][Full Text] [Related]
30. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Gupta NC; Frank AR; Dewan NA; Redepenning LS; Rothberg ML; Mailliard JA; Phalen JJ; Sunderland JJ; Frick MP
Radiology; 1992 Aug; 184(2):441-4. PubMed ID: 1620844
[TBL] [Abstract][Full Text] [Related]
31. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.
Lowe VJ; DeLong DM; Hoffman JM; Coleman RE
J Nucl Med; 1995 May; 36(5):883-7. PubMed ID: 7738668
[TBL] [Abstract][Full Text] [Related]
32. [Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan].
Kubota K; Yamada S; Fukuda H; Tanida T; Saitou Y; Takahashi J; Yamada K
Kaku Igaku; 1997 May; 34(5):329-36. PubMed ID: 9248260
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET.
Kim EE; Chung SK; Haynie TP; Kim CG; Cho BJ; Podoloff DA; Tilbury RS; Yang DJ; Yung WK; Moser RP
Radiographics; 1992 Mar; 12(2):269-79. PubMed ID: 1561416
[TBL] [Abstract][Full Text] [Related]
34. Blood flow and metabolism of central neurocytoma: a positron emission tomography study.
Mineura K; Sasajima T; Itoh Y; Sasajima H; Kowada M; Tomura N; Uesaka Y; Ogawa T; Hatazawa J; Uemura K
Cancer; 1995 Oct; 76(7):1224-32. PubMed ID: 8630902
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography in oncology.
Leskinen-Kallio S
Clin Physiol; 1994 May; 14(3):329-35. PubMed ID: 8026150
[TBL] [Abstract][Full Text] [Related]
36. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography.
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
Ann Thorac Surg; 1995 Nov; 60(5):1348-52. PubMed ID: 8526625
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of pulmonary lesions with positron emission tomography].
Knopp MV; Bischoff HG
Radiologe; 1994 Oct; 34(10):588-91. PubMed ID: 7816916
[TBL] [Abstract][Full Text] [Related]
38. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET.
Roelcke U; Radü EW; von Ammon K; Hausmann O; Maguire RP; Leenders KL
J Neurol Sci; 1995 Sep; 132(1):20-7. PubMed ID: 8523026
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography in oncology: the most sophisticated imaging technology.
Lacić M; Maisey MN; Kusić Z
Acta Med Croatica; 1997; 51(1):1-9. PubMed ID: 9115096
[TBL] [Abstract][Full Text] [Related]
40. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
